Janney Montgomery Scott’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$202M Sell
1,679,664
-132,888
-7% -$15.3M 0.5% 36
2025
Q4
$191M Sell
1,812,552
-38,495
-2% -$3.61M 0.44% 41
2025
Q3
$155M Buy
1,851,047
+6,642
+0.4% +$547K 0.37% 53
2025
Q2
$146M Sell
1,844,405
-42,991
-2% -$3.42M 0.38% 51
2025
Q1
$169M Sell
1,887,396
-15,113
-0.8% -$1.41M 0.48% 39
2024
Q4
$189M Buy
1,902,509
+35,525
+2% +$3.66M 0.52% 33
2024
Q3
$212M Buy
1,866,984
+37,216
+2% +$4.42M 0.59% 31
2024
Q2
$227M Buy
1,829,768
+72,199
+4% +$9.3M 0.69% 23
2024
Q1
$232M Buy
1,757,569
+4,179
+0.2% +$515K 0.69% 22
2023
Q4
$191M Sell
1,753,390
-116,212
-6% -$12.1M 0.62% 26
2023
Q3
$192M Buy
1,869,602
+11,911
+0.6% +$1.28M 0.72% 21
2023
Q2
$214M Buy
1,857,691
+8,699
+0.5% +$988K 0.75% 20
2023
Q1
$197M Sell
1,848,992
-27,928
-1% -$3.02M 0.8% 15
2022
Q4
$208M Sell
1,876,920
-4,042
-0.2% -$413K 0.81% 16
2022
Q3
$162M Buy
1,880,962
+76,484
+4% +$6.83M 0.69% 22
2022
Q2
$165M Buy
1,804,478
+159,397
+10% +$14.1M 0.75% 20
2022
Q1
$135M Buy
1,645,081
+28,745
+2% +$2.27M 0.58% 31
2021
Q4
$124M Buy
1,616,336
+18,166
+1% +$1.45M 0.48% 43
2021
Q3
$120M Buy
1,598,170
+22,374
+1% +$1.7M 0.51% 37
2021
Q2
$123M Buy
1,575,796
+23,024
+1% +$1.71M 0.54% 34
2021
Q1
$114M Buy
1,552,772
+11,761
+0.8% +$868K 0.56% 34
2020
Q4
$120M Buy
1,541,011
+53,007
+4% +$4.05M 0.58% 30
2020
Q3
$118M Buy
1,488,004
+49,895
+3% +$3.91M 0.67% 25
2020
Q2
$106M Buy
1,438,109
+220,070
+18% +$16.6M 0.67% 26
2020
Q1
$89.4M Buy
1,218,039
+105,601
+9% +$8.3M 0.71% 23
2019
Q4
$96.5M Sell
1,112,438
-12,112
-1% -$995K 0.63% 24
2019
Q3
$90.3M Buy
1,124,550
+17,666
+2% +$1.42M 0.66% 24
2019
Q2
$88.6M Buy
1,106,884
+2,591
+0.2% +$198K 0.68% 20
2019
Q1
$87.6M Buy
1,104,293
+23,406
+2% +$1.75M 0.72% 17
2018
Q4
$78.8M Buy
1,080,887
+19,162
+2% +$1.35M 0.76% 19
2018
Q3
$71.9M Buy
1,061,725
+26,644
+3% +$1.7M 0.62% 27
2018
Q2
$60M Buy
1,035,081
+2,275
+0.2% +$128K 0.58% 30
2018
Q1
$53.7M Buy
1,032,806
+104,881
+11% +$5.66M 0.54% 34
2017
Q4
$49.8M Buy
927,925
+40,486
+5% +$2.24M 0.52% 35
2017
Q3
$54.2M Buy
887,439
+7,465
+0.8% +$453K 0.62% 27
2017
Q2
$53.8M Buy
879,974
+10,761
+1% +$655K 0.67% 20
2017
Q1
$52.7M Sell
869,213
-9,368
-1% -$568K 0.7% 22
2016
Q4
$49.4M Buy
878,581
+34,664
+4% +$2.03M 0.74% 20
2016
Q3
$50.3M Buy
+843,917
New +$49.4M 0.89% 15
2016
Q2
Sell
-684,105
Closed -$34.5M 988
2016
Q1
$34.5M Buy
684,105
+73,452
+12% +$3.6M 0.9% 15
2015
Q4
$30.8M Sell
610,653
-7,935
-1% -$400K 0.79% 19
2015
Q3
$29.2M Buy
618,588
+20,739
+3% +$1.1M 0.82% 17
2015
Q2
$32.5M Buy
597,849
+24,137
+4% +$1.35M 0.68% 10
2015
Q1
$31.5M Buy
573,712
+15,266
+3% +$864K 0.59% 12
2014
Q4
$30.3M Buy
558,446
+21,992
+4% +$1.23M 0.61% 14
2014
Q3
$30.3M Buy
536,454
+15,430
+3% +$866K 0.63% 13
2014
Q2
$28.8M Buy
521,024
+12,745
+3% +$695K 0.63% 12
2014
Q1
$27.5M Sell
508,279
-10,003
-2% -$518K 0.67% 14
2013
Q4
$24.8M Sell
518,282
-5,894
-1% -$269K 0.65% 15
2013
Q3
$23.8M Buy
524,176
+370,070
+240% +$16.9M 0.72% 10
2013
Q2
$6.83M Buy
+154,106
New +$6.88M 0.71% 23

Other funds holding MRK

Janney Montgomery Scott's MRK Position: Q1 2026 in Review

Janney Montgomery Scott reduced its Merck (MRK) stake by 7.3% in Q1 2026, selling an estimated $15.3M and leaving 1,679,664 shares worth $202M. The position accounts for 0.5% of the portfolio, ranked #36.

Janney Montgomery Scott first reported a position in MRK in Q2 2013 and has held it in 51 quarters since. The position peaked at $232M in Q1 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Janney Montgomery Scott held 1,679,664 shares of Merck worth $202M as of Q1 2026.
  • Janney Montgomery Scott sold 132,888 Merck shares in Q1 2026, an estimated $15.3M.
  • Merck made up 0.5% of Janney Montgomery Scott's portfolio in Q1 2026, its #36 holding.
  • Janney Montgomery Scott first reported a position in Merck in Q2 2013 and has held it in 51 quarters since.
  • Janney Montgomery Scott's Merck position peaked at $232M in Q1 2024.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Janney Montgomery Scott's 13F filing for Q1 2026, filed 22 Apr 2026.